Morbidity and mortality associated with Farber disease and prospects for therapy

References

• Farber S. A lipid metabolic disorder – disseminated “Lipogranulomatosis” – a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-Schuller-Christian disease. Am J Dis Child. 1952;84:499.
   Google Scholar
• Schultze G, Lang EK. Disseminated Lipogranulomatosis. Report of a case. Radiology. 1960;74:428–431.
   Google Scholar
• Zetterstrom R. Disseminated Lipogranulomatosis (Farber’s disease). Acata Paediatrica. 1958;47:501–510.
   Google Scholar
• Sugita M, Moser HW, Dulaney JT. (Ceramidase deficiency in Farbers disease (lipogranulomatosis). Science. 1972;178:1100–1103.
   Google Scholar
• Moser HW, Linke T, Fensom AH, et al. Acid ceramidase deficiency: Farber’s lipogranulomatosis. In: Scriver CR, Beaudet AL, Valle D, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed New York (NY): McGraw-Hill; 2001. p. 820–830.
   Google Scholar
• Fusch C, Huenges R, Moser HW, et al. A case of combined Farber and Sandhoff disease. Eur J Pediatr. 1989;148:558–562.
   Google Scholar
• Schnabel D, Schroder M, Furst W, et al. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem. 1992;267:3312–3315.
   Google Scholar
• Levade T, Sandhoff K, Schulze H, et al. Acid ceramidase deficiency: Farber lipogranulomatosis. In: Valle D, Beaudet AL, Vogelstein B, et al. editors. Online metabolic and molecular basis of human disease. 2009. Chapter 143. Available from: http://www/ommbid.com
   Google Scholar
• Zhou J, Tawk M, Tiziano FD, et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in asah1. Am J Hum Genet. 2012;91:5–14.
   Google Scholar
• Jankociv J, Rivera V. Hereditary myoclonus and progessive muscular atrophy: a new syndrome. Trans Am Neurol Assoc. 1978;278:116–118.
   Google Scholar
• Dyment DA, Sell E, Vanstone MR, et al. Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy. Clin Genet. 2014;86:558–563.
   Google Scholar
• Gan JJ, Garcia V, Tian J, et al. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. Neuromuscul Disord. 2015;25:959–963.
   Google Scholar
• Rubboli G, Veggiotti P, Pini A, et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy: a rare condition caused by mutations in ASAH1. Epilepsia. 2015;56:692–698.
   Google Scholar
• Bonafe L, Kariminejad A, Li J, et al. Peripheral osteolysis in adults linked to ASAH1 (acid ceramidase) mutations: a new presentation of Farber disease. Arthritis Rheumatol. 2016;68:2323–2327.
   Google Scholar
• Teoh HL, Solyom A, Schuchman EH, et al. Polyarticular arthritis and spinal muscular atrophy in acid ceramidase deficiency. Pediatrics. 2016;138:pii: e20161068.
   Google Scholar
• Gatt S. Enzymic hydrolysis and synthesis of ceramides. J Biol Chem. 1963;2383:131–133.
   Google Scholar
• Bernardo K, Hurwitz R, Zenk T, et al. Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem. 1995;270:11098–11102.
   Google Scholar
• Ferlinz K, Kopal G, Bernardo K, et al. Human acid ceramidase: processing, glycosylation, and lysosomal targeting. J Biol Chem. 2001;276:35352–35360.
   Google Scholar
• He X, Okino N, Dhami R, et al. Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem. 2003;278:32978–32986.
   Google Scholar
• Shtraizent N, Eliyahu E, Park JH, et al. Autoproteolytic cleavage and activation of human acid ceramidase. J Biol Chem. 2008;283:11253–11259.
   Google Scholar
• Hannun YA, Obeid LM. Many ceramides. J Biol Chem. 2008;286:27855–27862.
   Google Scholar
• Linke T, Wilkening G, Sadeghlar F, et al. Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J Biol Chem. 2001;276:5760–5768.
   Google Scholar
• Ferraz MJ, Marques AR, Marques MD, et al. Lysosomal glycosphingolipid catabolsim by acid ceramidase: formation of glycosphingolipid bases during deficiency of glycosidases. FEBS Lett. 2016;59:716–725.
   Google Scholar
• Okino N, He X, Gatt S, et al. The reverse activity of human acid ceramidase. J Biol Chem. 2003;278:29948–29953.
   Google Scholar
• Koch J, Gartner S, Li CM, et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease. J Biol Chem. 1996;271:33110–33115.
   Google Scholar
• Li CM, Park JH, He X, et al. The human acid ceramidase gene (asah): structure, chromosomal location, mutation analysis, and expression. Genomics. 1999;62:223–231.
   Google Scholar
• Al Jasmi F. A novel mutation in an atypical presentation of the rare infantile Farber disease. Brain Dev. 2012;34:533–535.
   Google Scholar
• Bashyam MD, Chaudhary AK, Kiran M, et al. Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation. Clin Genet. 2014;86:530–538.
   Google Scholar
• Alves MQ, Le Trionnaire E, Ribeiro I, et al. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene. Mol Genet Metab. 2013;109:276–281.
   Google Scholar
• Bar J, Linke T, Ferlinz K, et al. Molecular analysis of acid ceramidase deficiency in patients with Farber disease. Hum Mutat. 2001;17:199–209.
   Google Scholar
• Levade T, Enders H, Schliephacke M, et al. Neurodegenerative course in ceramidase deficiency (Farber disease) correlated with the residual lysosomal ceramide turnover in cultured living patient cells. J Neurol Sci. 1995;134:108–114.
   Google Scholar
• Li CM, Hong SB, Kopal G, et al. Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics. 1998;50:267–274.
   Google Scholar
• Li CM, Park JH, Simonaro CM, et al. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics. 2002;79:218–224.
   Google Scholar
• Eliyahu E, Park JH, Shtraizent N, et al. Acid ceramidase is a novel factor required for early embryo survival. FASEB J. 2007;21:1403–1409.
   Google Scholar
• Eliyahu E, Shtraizent N, Martinuzzi K, et al. Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. FASEB J. 2010;24:1229–1238.
   Google Scholar
• Eliyahu E, Shtraizent N, Shalgi R, et al. Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility. Cell Physiol Biochemistry. 2012;30:735–748.
   Google Scholar
• Alayoubi AM, Wang JC, Au BC, et al. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013;5:827–842.
   Google Scholar
• Sikora J, Dworski S, Kamani MA, et al. Acid ceramidase deficiency in mice results in a broad range of central nervious system abnormalities. Am J Pathol. 2017;187:864–883.
   Google Scholar
• Dworski S, Berger A, Furlonger C, et al. Markedly perturbed hematopoiesis in acid ceramidase deficient mice. Haematologica. 2015;100:e162–5.
   Google Scholar
• Dworski S, Lu P, Khan A, et al. Acid ceramidase deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta. 2017;1863:386–394.
   Google Scholar
• He X, Dworksi S, Zhu C, et al. Enzyme replacement therapy for Farber disease: proof-of-concept studies in cells and mice. BBA Clinical. 2017;7:85–96.
   Google Scholar
• Solyom A, Nwosu EO, Mitchell J, et al. Farber disease (acid ceramidase deficiency) epidemiology: literature review and patient cohort data indicate moderate and attenuated phenotypes are likely underrepresented in the medical literature and are underdiagnosed. Mol Gen Metab. 2017;120:suppl124–5.
   Google Scholar
• Solyom A, Ehlert K, Hügle B, et al. Farber disease: first natural history cohort demonstrates a broad clinical spectrum with implications for juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74:suppl2838.
   Google Scholar
• Moser HW, Chen WW. Ceramidase deficiency: Farber’s lipogranulomatosis. In:Stanbury JB, Wyngaarden JB, Fredrickson DS, et al., editors. Metabolic basis of inherited disease. 5th ed. New York (NY):McGraw Hill; 1983. p.1645–1654.
   Google Scholar
• Qualman S, Moser H, Valle D, et al. Farber disease: pathologic diagnosis in sibs with phenotypic variability. Am J Med Genet Suppl. 1987;3:233–241.
   Google Scholar
• Nowaczyk MJ, Feigenbaum A, Silver MM, et al. Bone marrow involvement and obstructive jaundice in Farber lipogranulomatosis: clinical and autopsy report of a new case. J Inherit Metab Dis 1996;19:655–660
   Google Scholar
• Jarisch A, Steward CG, Sörensen J, et al. Odontoid infiltration and spinal compression in Farber disease: reversal by haematopoietic stem cell transplantation. Eur J Pediatr. 2014;173:1399–1403.
   Google Scholar
• Schäfer A, Hartzer K, Kattner E, et al. Disseminated lipogranulomatosis (Farber disease) with hydrops fetalis. Pathologie. 1996;17:145–149. [German]
   Google Scholar
• Hügle B, Mueller L, Levade T. Why Farber disease may be misdiagnosed as juvenile idiopathic arthritis. The Rheumatologist. 2014. Available from: http://www.the-rheumatologist.org/article/why-farber-disease-may-be-misdiagnosed-as-juvenile-idiopathic-arthritis/
   Google Scholar
• Kostik M, Chikova I, Avramenko V, et al. Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. J Inherit Metab Dis. 2013;36:1079–1080.
   Google Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and hunter syndromes: mutual cross-correction of the defect in cultured fibroblasts. Science. 1968;162:570–572.
   Google Scholar
• Reitman ML, Kornfeld S. UDP-N-acetylglucosamine-1-phosphotransferase. Proposed enzyme for the phosphorylation of the high mannose oligosaccharide units of lysosomal enzymes. J Biol Chem. 1981;256:4275–4281.
   Google Scholar
• Hobbs JR. Bone marrow transplantation in genetic diseases. Eur J Pediatr. 1982;151(Suppl 1):S44–49.
   Google Scholar
• Krivit W. Allogenic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol. 2004;26:119–132.
   Google Scholar
• Orchard PJ, Blazar BR, Wagner J, et al. Hematopoietic cell therapy for metabolic disease. J Pediatr. 2007;151:340–346.
   Google Scholar
• Krall WJ, Challita PM, Perlmutter LS, et al. Cells expressing human glucocerebrosidase from a retroviral vector repopulate macrophages and central nervous system microglia after murine bone marrow transplantation. Blood. 1994;83:2737–2748.
   Google Scholar
• Malatack JJ, Consolini DM, Bauyever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatric Neurol. 2003;29:391–393.
   Google Scholar
• de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.
   Google Scholar
• Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood. 1997;90:986–993.
   Google Scholar
• Souillet G, Guiband P, Fenson AH, et al. Outcome of displacement of bone marrow transplantation in Farber’s disease: a report of a case. In: Hobbs JR, editor. Correction of certain genetic diseases by transplantation COGENT. London; 1989. p. 137–141.
   Google Scholar
• Yeager AM, Uhas KA, Coles CD, et al. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant. 2000;26:357–363.
   Google Scholar
• Torcoletti M, Petaccia A, Pinto RM, et al. Farber disease in infancy resembling juvenile idiopathic arthritis: identification of two new mutations and a good early response to allogeneic haematopoietic stem cell transplantation. Rheumatology (Oxford). 2014;53:1533–1534.
   Google Scholar
• Cappellari AM, Torcoletti M, Triulzi F, et al. Nervous system involvement in Farber disease. J Inherit Metab Dis. 2016;39:149–150.
   Google Scholar
• Ehlert K, Frosch M, Fehse N, et al. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J. 2007;5:15.
   Google Scholar
• Vormoor J, Ehlert K, Groll AH, et al. Successful hematopoietic stem cell transplantation in Farber disease. J Pediatr. 2004;144:132–134.
   Google Scholar
• Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471–486.
   Google Scholar
• Hollak CE, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis. 2014;37:587–598.
   Google Scholar
• Giugliani R, Federhen A, Vairo F, et al. Emerging drugs for the treatment of mucopolysaccharidoses. Exprt Opin Emerg Drugs. 2016;21:9–26.
   Google Scholar
• Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307–335.
   Google Scholar
• Gatt S. Enzymatic hydrolysis of sphingolipids. I. Hydrolysis and synthesis of ceramides by an enzyme from rat brain. J Biol Chem. 1966;241:3724–3730.
   Google Scholar
• Schulze H, Schepers U, Sandhoff K, et al. Overexpression and mass spectrometry analysis of mature human acid ceramidase. Biol Chem. 2007;388:1333–1343.
   Google Scholar
• Medin JA, Takenaka T, Carpentier S, et al. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. Hum Gene Ther. 1999;10:1321–1329.
   Google Scholar
• Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012;52:6–17.
   Google Scholar
• Saied EM, Arenz C. Inhibitors of ceramidases. Chem Phys Lipids. 2015;197:60–68.
   Google Scholar
• Cox TM. Innovative treatments for lysosomal diseases. Best Pract Res Clin Endocrinol Metab. 2015;29:275–311.
   Google Scholar
• Pewzner-Jung Y, Tavakoli-Tabazaverh S, Grassme H, et al. Sphingoid long chain bases prevent lung infections in Pseudomonas aeurginosa. EMBO Mol Med. 2014;6:1205–1214.
   Google Scholar
• Mitchell J, Solyom A, Makay B, et al. Farber disease: implications of anti-inflammatory treatment. Mol Gen Metab. 2016;117(Suppl):81–82.
   Google Scholar
• Espaillat MP, Kew RR, Obeid LM. Sphingolipids in neutrophil function and inflammatory responses: mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. Adv Biol Regul. 2017;63:140–155.
   Google Scholar